The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)



Gene Review

NRSN1  -  neurensin 1

Homo sapiens

Synonyms: Neurensin-1, Neuro-p24, VMP, Vesicular membrane protein of 24 kDa, Vesicular membrane protein p24, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of NRSN1


Psychiatry related information on NRSN1


High impact information on NRSN1

  • This phase 1/2 trial in 60 untreated MM patients aged at least 65 years (half older than 75 years) was designed to determine dosing, safety, and efficacy of bortezomib plus MP (VMP) [1].
  • VMP response rate was 89%, including 32% immunofixation-negative CRs, of whom half of the IF(-) CR patients analyzed achieved immunophenotypic remission (no detectable plasma cells at 10(-4) to 10(-5) sensitivity) [1].
  • One hundred fifteen patients with metastatic carcinoma of the breast were treated in a randomized trial of mitoxantrone (Novantrone, Lederle Laboratories, Pearl River, NY) combined with vincristine and prednisolone (VMP) or doxorubicin (Adriamycin, Adria Laboratories, Columbus, OH) combined with vincristine and prednisolone (VAP) [2].
  • So it is speculated that VMP may associated with microtubules through its C-terminal and plays an important role in vesicular organelles transport and nerve signals [8].
  • We performed a prospective study to evaluate the feasibility and activity of a second-line chemotherapy regimen consisting of etoposide, mitoxantrone, and prednimustine (VMP) in this setting [9].

Associations of NRSN1 with chemical compounds


Analytical, diagnostic and therapeutic context of NRSN1

  • RT-PCR analysis shows that VMP is expressed exclusively in brain of the 16 tissues examined, suggesting that it is a neuron-specific membrane protein [8].
  • At 2 years, the progression-free survival (PFS) rate was 25% with VMP versus 55% with CHOP (P = .002) and the overall survival (OS) rate was 30% with VMP versus 65% with CHOP (P = .004) [11].
  • Based on the response rate obtained with combined chemotherapy, a randomized trial of VMP initial chemotherapy is currently being undertaken by our cooperative group to study whether such an initial treatment could improve resectability and radiation-mediated local control along with survival rate [12].
  • Although the overall prognosis of patients with resistant or relapsed HIV-NHL is very poor, palliative therapy with VMP can be effective and relatively safe in the latter group [9].
  • The 'second turning point' (1976-1980), characterized by introduction of the systematic conventional polychemotherapy (VMP, VMCP, VBAP, VCAP) and complex supportive treatment, was associated with subsequent improvement of therapeutic response (OS 40 months, P=0.0000; 3- or 10-year survival was seen in 55 and 5.5% of patients) [13].


  1. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study. Mateos, M.V., Hernández, J.M., Hernández, M.T., Gutiérrez, N.C., Palomera, L., Fuertes, M., Díaz-Mediavilla, J., Lahuerta, J.J., de la Rubia, J., Terol, M.J., Sureda, A., Bargay, J., Ribas, P., de Arriba, F., Alegre, A., Oriol, A., Carrera, D., García-Laraña, J., García-Sanz, R., Bladé, J., Prósper, F., Mateo, G., Esseltine, D.L., van de Velde, H., Miguel, J.F. Blood (2006) [Pubmed]
  2. Mitoxantrone versus doxorubicin in combination chemotherapy for advanced carcinoma of the breast. Leonard, R.C., Cornbleet, M.A., Kaye, S.B., Soukop, M., White, G., Hutcheon, A.W., Robinson, S., Kerr, M.E., Smyth, J.F. J. Clin. Oncol. (1987) [Pubmed]
  3. A prospective study of a new combination chemotherapy regimen in patients older than 70 years with unfavorable non-Hodgkin's lymphoma. Tirelli, U., Zagonel, V., Errante, D., Serraino, D., Talamini, R., De Cicco, M., Carbone, A., Monfardini, S. J. Clin. Oncol. (1992) [Pubmed]
  4. Genetic and immunological analyses of Vls (VMP-like sequences) of Borrelia burgdorferi. Kawabata, H., Myouga, F., Inagaki, Y., Murai, N., Watanabe, H. Microb. Pathog. (1998) [Pubmed]
  5. Treatment of lymphoma in the elderly: an update. Tirelli, U., Zagonel, V., Errante, D., Fratino, L., Monfardini, S. Rays. (1997) [Pubmed]
  6. Strong genetic evidence of DCDC2 as a susceptibility gene for dyslexia. Schumacher, J., Anthoni, H., Dahdouh, F., König, I.R., Hillmer, A.M., Kluck, N., Manthey, M., Plume, E., Warnke, A., Remschmidt, H., Hülsmann, J., Cichon, S., Lindgren, C.M., Propping, P., Zucchelli, M., Ziegler, A., Peyrard-Janvid, M., Schulte-Körne, G., Nöthen, M.M., Kere, J. Am. J. Hum. Genet. (2006) [Pubmed]
  7. Event-related potentials during digit recognition tasks. Ji, J., Porjesz, B., Chorlian, D., Begleiter, H. Brain research. Cognitive brain research. (1998) [Pubmed]
  8. Cloning, expression and characterization of a novel human VMP gene. Cheng, C., Xu, J., Ye, X., Dai, J., Wu, Q., Zeng, L., Wang, L., Zhao, W., Ji, C., Gu, S., Xie, Y., Mao, Y. Mol. Biol. Rep. (2002) [Pubmed]
  9. Second-line chemotherapy in human immunodeficiency virus-related non-Hodgkin's lymphoma: evidence of activity of a combination of etoposide, mitoxantrone, and prednimustine in relapsed patients. Tirelli, U., Errante, D., Spina, M., Gastaldi, R., Nigra, E., Nosari, A.M., Magnani, G., Vaccher, E. Cancer (1996) [Pubmed]
  10. Phase III study of intermittent 5-drug regimen (VBCMP) versus intermittent 3-drug regimen (VMP) versus intermittent melphalan and prednisone (MP) in myelomatosis. Hansen, O.P., Clausen, N.A., Drivsholm, A., Laursen, B. Scandinavian journal of haematology. (1985) [Pubmed]
  11. CHOP is the standard regimen in patients > or = 70 years of age with intermediate-grade and high-grade non-Hodgkin's lymphoma: results of a randomized study of the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Study Group. Tirelli, U., Errante, D., Van Glabbeke, M., Teodorovic, I., Kluin-Nelemans, J.C., Thomas, J., Bron, D., Rosti, G., Somers, R., Zagonel, V., Noordijk, E.M. J. Clin. Oncol. (1998) [Pubmed]
  12. Squamous cell carcinoma of the esophagus. Treatment by combined vincristine-methotrexate plus folinic acid rescue and cisplatin before radiotherapy. Resbeut, M., Le Prise-Fleury, E., Ben-Hassel, M., Goudier, M.J., Morice-Rouxel, M.F., Douillard, J.Y., Chenal, C. Cancer (1985) [Pubmed]
  13. Results of therapy and changing prognosis of multiple myeloma during the last 40 years in the region of North and Middle Moravia: group of 562 patients. Scudla, V., Bacovsky, J., Indrak, K., Kodouskova, V., Vytrasova, M., Faber, E., Papajik, T., Adam, Z., Hajek, R., Horak, P., Martinek, A. Hematol. J. (2003) [Pubmed]
WikiGenes - Universities